TH V THL
Phase 3 Completed
75 enrolled
TOUCH
Phase 2 Completed
147 enrolled 11 charts
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase 2 Completed
90 enrolled
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Phase 1 Completed
15 enrolled
FB-12
Phase 2 Unknown
64 enrolled
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Phase 2 Completed
141 enrolled 16 charts
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Phase 3 Completed
2,130 enrolled
BETH
Phase 3 Terminated
3,509 enrolled
TREAT-CTC
Phase 2 Completed
1,317 enrolled
TCHL Phase II
Phase 2 Completed
120 enrolled
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
Phase 1/2 Completed
129 enrolled
CADY Study ICORG 08-01
Completed
480 enrolled
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Phase 1 Completed
21 enrolled
ABCSG 32
Phase 2 Completed
100 enrolled
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Phase 2 Completed
76 enrolled 6 charts
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1 Completed
23 enrolled
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Phase 3 Completed
536 enrolled
Phase II Study in Patients With Operable Breast Cancer
Phase 2 Unknown
30 enrolled